US › Healthcare

Kalvista Pharmaceuticals Inc (KALV)

US · Healthcare · Biotechnology

$27.000.00%
Last close · 2026-08-04

Latest quarter · ended 2026-04-30

Revenue
$59.9M
Net profit
$-5.4M
Profit YoY
+89.7%
EPS
$-0.43
EPS estimate
$-0.38
Net margin
-9.0%

EPS came in at -0.43 against a street estimate of -0.38 — a miss of 14.3%.

Key statistics

Market cap
$1.44B
Forward P/E
25.4
P/B
49.03
Book value
$-0.38
EPS (TTM)
$-3.94
52-week high
$27.00
52-week low
$10.41
50-day MA
$24.43
200-day MA
$17.09
Beta
-0.11

Analyst view

Analysts rate Kalvista Pharmaceuticals Inc a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $27.00.

Shareholding

Insiders
1.72%
Institutions
136.88%

Largest institutional holders

FundStake
VR Adviser, LLC12.16%
Frazier Life Sciences Management, L.P.9.32%
Suvretta Capital Management, LLC8.96%
TANG CAPITAL MANAGEMENT LLC8.59%
BlackRock Inc7.13%
SILVERARC CAPITAL MANAGEMENT, LLC5.40%
Capital World Investors5.28%
Vanguard Group Inc4.71%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kalvista Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.